Developing next-generation mRNA-LNP therapeutics that selectively modulate or deplete pathogenic immune cells to treat type 1 diabetes, lupus, multiple sclerosis, and other severe autoimmune conditions.
Developing 10E5-1, an anti-activin A antibody delivered via mRNA-LNP, to suppress pathogenic antibody production and treat rheumatoid arthritis through a novel mechanism.
Identifying urine DNA methylation signatures as a non-invasive biomarker for lupus nephritis class and disease progression.
Profiling immune responses in severe asthma patients before and after biologic treatment to identify biomarkers of response and novel drug targets.
Using temporal graph machine learning and deep immune profiling to predict which cancer immunotherapy patients will develop autoimmune adverse events before they occur.
Investigating the autoimmune and immune dysregulation mechanisms underlying Long COVID to improve diagnosis, treatment, and biological understanding of persistent symptoms.
Identifying the autoantigens and T cell clonotypes driving immune attack in aplastic anemia to enable more precise diagnostics and targeted therapies.
Identifying GSPT1 as an essential, targetable vulnerability of skin-resident memory T cells to enable durable remission in chronic inflammatory skin diseases without systemic immunosuppression.
Building the largest cerebrospinal fluid immune profile dataset in pediatric autoimmune neurological diseases to enable faster, more accurate diagnosis of MS and related conditions.
Building a CHO cell surface display library of all human proteins to enable comprehensive, high-throughput autoantibody profiling across autoimmune diseases and vaccine responses.
